From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
Since 2015, the 340B program has grown explosively. The number of new covered entity sites increased by more than 16,000 locations, and registered contract pharmacies have ballooned by 31,188. Paralleling the overall market trend, there are now over 10,000 specialty pharmacies acting as contract pharmacies.
While 340B sales represents only about 6% of total pharmaceutical sales overall, the mix of 340B business is well over 50% of sales for Oncology, Immunology, and other specialty therapies. The 340B influence is a major factor in the escalation in list prices for innovative drugs.
Your team needs data and analytics solutions to investigate instances of non-compliance, specifically diversion and duplicate discounting. Using our ICyte Platform to crosswalk pharmacy sell-in data, rebates, and chargebacks, your team can identify non-compliant 340B transactions.
Our 340B Analytics offers enriched 340B-focused visualizations including commercial and 340B transactions across every covered entity and covered entity site of care, including contract pharmacies.
